Department of Ecology and Evolutionary Biology, Princeton University, NJ, USA.
Lancet. 2013 Oct 19;382(9901):1373-9. doi: 10.1016/S0140-6736(13)60896-X. Epub 2013 May 29.
Universal access to high-quality treatment is central to the Global Plan to Stop TB. The Global Drug Facility (GDF) was launched in 2001 to help to achieve this goal, through services including the supply of affordable, quality-assured drugs to countries in need. We assess the scale of GDF drug supplies worldwide and find that the GDF commands a substantial proportion of the market for drugs for first-line and second-line treatment regimens, having supplied, for example, first-line drugs for roughly 35% of cases reported worldwide in 2011. Significant potential remains for GDF expansion, especially in the provision of second-line drugs, which would be aided by future increases in case detection.
普及高质量的治疗是全球结核病计划的核心。全球药品基金（GDF）成立于 2001 年，旨在通过提供负担得起的、质量保证的药物等服务来帮助实现这一目标，以满足有需要的国家的需求。我们评估了全球 GDF 药品供应的规模，发现 GDF 在一线和二线治疗方案的药物市场中占据了相当大的份额，例如，2011 年全球报告的病例中，大约有 35%的病例使用了 GDF 提供的一线药物。GDF 仍有很大的扩展潜力，特别是在二线药物的供应方面，如果未来的病例检出率提高，将会得到帮助。
